BioSpace News Archive

Innovent Biologics, Inc. announced that clinical data of IBI188 as first-line treatment in newly diagnosed higher risk myelodysplastic syndrome is presented at the 2022 American Society of Hematology Annual Meeting, held Dec 10-13, 2022.

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced an oral, encore presentation of clinical data from patients with sickle cell disease or transfusion-dependent beta-thalassemia treated with the investigational therapy exagamglogene autotemcel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study.

Adaptive Biotechnologies Corporation announced new data demonstrating the strengths of Adaptive’s next-generation sequencing -based clonoSEQ® Assay in measuring minimal residual disease in blood cancer patients.

Orum Therapeutics announced the presentation of positive preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia, at the 64th American Society of Hematology Annual Meeting & Exposition taking place December 10-13 in New Orleans and virtually.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with Vidaza® and Venclexta® in patients with relapsed/refractory and frontline acute myeloid leukemia.

MaaT Pharma presented data from the continuing compassionate use program in France for MaaT013 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf, bispecific T-cell engager antibody.

Pfizer Inc. announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen -CD3-targeted bispecific antibody, is efficacious and has a manageable safety profile in patients with relapsed or refractory multiple myeloma in a heavily pretreated population, who have received at least three classes of prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Tessa Therapeutics Ltd. announced enhanced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.